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ABSTRACT
Aims: This trial-based economic evaluation (EE) assesses from a societal perspective the cost-effective-
ness of an intensive 3-day cognitive theory-based intervention (CDT), compared to care-as-usual, in
patients with relapsing remitting multiple sclerosis (RRMS) and low disability (Expanded Disability
Status Scale [EDDS] score < 4.0).
Materials and methods: The trial of the EE was registered in the Dutch Trial Register: Trial NL5158
(NTR5298). The incremental cost-effectiveness ratio (ICER) was expressed in cost on the Control sub-
scale of the Multiple Sclerosis Self-Efficacy Scale (MSSES) and the incremental cost-utility ratio (ICUR) in
the cost per Quality Adjusted Life Years (QALY) using the EQ-5D-5L. Bootstrap, sensitivity, and sub-
group analyses were performed to determine the robustness of the findings.
Results: The two groups of 79 patients were similar in baseline characteristics. The base case ICER is
situated in the northeast quadrant (e72 (40.74/e2,948)) due to a higher MSSES Control score and
higher societal costs in the CDT group. The ICUR is situated in the northwest (inferior) quadrant due
to losses in QALY and higher societal costs for the CDT group (0.02/e2,948). Overall, bootstrap, sensi-
tivity, and sub-group analyses confirm the base case findings. However, when the SF-6D is used as a
study outcome, there is a high probability that the ICUR is situated in the northeast quadrant.
Limitations: The relative short follow-up time (6months) and the unexpected increase in MSSES
Control in the control group.
Conclusions: When using the EQ-5D-5L to calculate a QALY, CDT is not a cost-effective alternative in
comparison to care as usual. However, when using self-efficacy or SF-6D as outcomes, there is a prob-
ability that CDT is cost-effective. Based on the current results, CDT for patients with RRMS clearly show
its potential. However, an extended follow-up for the economic evaluation is warranted before a final
decision on implementation can be made.
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Multiple sclerosis (MS) is a chronic disease of the central ner-
vous system, with an estimated worldwide prevalence of 2.5
million1. Of these patients with MS, 85% have been diag-
nosed with relapsing remitting MS (RRMS) at onset. This type
of MS is characterized by relapses that are followed by remis-
sions2. Frequently reported problems are fatigue, pain, cogni-
tive impairment, anxiety, and depression3. Due to the
symptoms and unpredictability of the disease, patients with
MS experience numerous problems in daily life. They might
not able to continue working in paid jobs, doing usual
household tasks, or taking care of children as healthy people
of their age would do4. Although there are various disease-
modifying drugs available for the treatment of RRMS, the
effectiveness of treatment and the resulting outcomes in
individual patients are variable and unpredictable.
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Self-efficacy is a psychological concept which is used to
provide insight into the degree a person is confident to
reach goals5. In patients with MS, low self-efficacy has been
associated with low health-related quality-of-life (HRQoL) and
less psychological adjustment. Several randomized clinical
trials have been performed in the UK and US evaluating the
effect on self-efficacy of non-pharmacological interventions
in patients with MS6–14. The interventions that were eval-
uated in five studies showed a significant positive effect on
the improvement of self-efficacy6,7,9,10,12. Other studies could
not find a relevant difference between the treatment
arms8,11,13,14. In the Netherlands, an intensive social cognitive
theory-based intervention with the participation of support-
ing partners, the Can Do treatment (CDT), has been devel-
oped and evaluated through an uncontrolled observational
study in patients with MS15. The results of this study were
promising: at the 6months follow-up, control self-efficacy
(i.e. confidence with managing symptoms and coping with
the demands of illness) and mental HRQoL had improved by
24.8% and 22.3%, respectively, in the RRMS sub-group, and
by 23.8% and 19.3%, respectively, in the low-disability group
(Expanded Disability Status Scale [EDDS] score < 4.0).
Comparable trends in time were observed in the effective-
ness analyses of a randomized controlled trial in both the
CDT and control group16. In the low-disability RRMS patients,
an intensive social cognitive treatment improved self-efficacy
control at 1 and 3 months, but not at 6 months compared
with usual care.
Due to the continually ongoing developments of new and
expensive treatment options, healthcare costs are increasing
in western countries. As healthcare budgets are limited,
however, there is a need for studies evaluating the cost-
effectiveness of these newly-developed interventions, to
keep healthcare sustainable into the future. This is also the
case for chronic diseases like MS. The estimated average
healthcare costs per RRMS patient range from 18,000–30,000
Euros per year in the Netherlands for those with EDSS scores
lower than 4.0; these costs are higher than or comparable to
other chronic diseases17. Healthcare costs are only part of
the costs for society, because non-healthcare costs, such as
the cost of productivity losses and informal care, must also
be considered.
Based on the promising results of the single-arm study15
and the need for cost-effectiveness analyses, a randomized
controlled study was designed to evaluate both the clinical
and economic effectiveness of the CDT intervention as previ-
ously investigated15,16. The current trial-based economic
evaluation aims to evaluate the cost-effectiveness from a
societal perspective in patients with RRMS with low disability.
The results of the clinical effectiveness will be reported
elsewhere16.
Methods
Study design and participants
The current study describes the economic evaluation
attached to a single-centre, parallel group, unmasked,
randomized controlled trial (RCT) with two groups. Patients
with MS were recruited by the National Multiple Sclerosis
Foundation in the Netherlands. The Medical Ethics
Committee in Tilburg (the Netherlands) has approved the
protocol of the study (NL number: NL4220502812). The study
was performed in agreement with the Declaration of
Helsinki, version 201318. The trial of the EE was registered
in the Dutch Trial Register: Trial NL5158 (NTR5298)
(https://www.trialregister.nl). Detailed information on the
methods of the trial19 and the effectiveness study can be
found elsewhere16. The eligibility criteria for patients were:
diagnosis of RRMS, being diagnosed at least 1 year before
study participation, EDSS score  4.0, no symptoms suggest-
ive of a relapse, no relapse in the preceding 4 weeks, willing
and capable of participating in the investigations, and having
access to the internet and having given written
informed consent.
Procedures
Eligibility checks and baseline assessment were done before
the start of the intervention. After the baseline assessment
(T0), follow-up assessments took place at 1 month (T1), 3
months (T2), and 6 months (T3). The 6-month follow up of
the study was chosen as the observational study previously
performed in MS patients with the same intervention in the
Netherlands showed an effect after 6months15. In addition,
in a chronic disorder like MS, an effect shorter than 6months
would have limited clinical relevance.
The CDT treatment was given by a multi-disciplinary team
and consists of large group sessions, small group sessions,
consultations, theatre evening, and (optional) a joint activity
at the start of the day. In large group sessions given by the
psychiatrist and psychiatric nurse, the participants were
taught the basics of how to support each other, give and
provide feedback. Potential stressors were identified for
every person, and one or two individual goals were formu-
lated. In small group sessions, participants could sign up for
different training groups depending on the defined goals.
For instance, sessions coached by a physiotherapist focusing
on exploration of physical capabilities, sessions coached by a
psychiatrist and psychiatric nurse targeting the emotional
potential, and “life” sessions coached by a neurologist, a reg-
istered nurse specialized in MS, and a person with MS, with
the focus on the exploration of capabilities relating to daily
living. There were relaxing sessions (coached by a dance
therapist) and a theatre evening (guided by the team) where
participants practiced changing roles to show potential by
experimentation. In the morning, the participants could par-
ticipate in a walk into the woods19.
The control group patients received care as usual, includ-
ing treatment and care by their neurologist or other health-
care professionals, as there is no standard treatment
available for the improvement of self-efficacy control in
patients with MS; they also had the option to receive CDT
after study participation. In the Netherlands, a National
Guideline for diagnosis and treatment of MS is used20.
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During the entire follow-up period, CDT patients were
allowed to contact the psychiatrist of the CDT team accord-
ing to need.
Randomization and blinding
Randomization was performed by Signidat, an independent
statistical agency in Groningen (the Netherlands), who gener-
ated the sequence. A stratified block randomization was
used for this, with disease duration and gender as blocking
factors for every CDT patient. Patients who were included in
the CDT group were phoned and invited by the project
coordinator of the National Multiple Sclerosis Foundation of
the Netherlands. Patients randomized into the control group
were also informed by phone and were given the opportun-
ity to receive CDT after the 6months study participation.
All questionnaires on resource use and outcomes were
filled in online (LimeSurvey). The items on the questionnaires
were fixed, and the responses were captured automatically.
Patients received reminders whenever questionnaires were
not completed. Reasons for not responding were also
stocked. The person (MH) who enrolled the patients was also
involved in the logistics of conducting the trial and in
providing a part of the CDT. The researcher (GvM) who
performed all analyses was masked from the treatment
group whenever possible during the analyses. It was not
possible to mask patients and the clinical investigator (PJJ)
for allocation of treatment.
Outcomes
For the cost-effectiveness analysis (CEA), control self-efficacy,
measured by the Multiple Sclerosis Self-Efficacy Scale
(MSSES), was used as the primary outcome. The MSSES is an
18-item questionnaire, containing two sub-scales, Control
and Function, each with nine questions scored on a 10-point
Likert scale from 10 (very uncertain) to 100 (very certain).
The MSSES is a disease-specific and sensitive questionnaire
with a high internal consistency and test–re-test reliability21.
For this analysis only MSSES Control data were used, with
higher scores on the sub-scale indicating more confidence in
managing symptoms and coping with the demands of ill-
ness. The validity and reliability of the MSSES has been
determined in previous research21.
The main outcome for the cost-utility analysis (CUA) was
HRQoL, as measured by the five-dimensional five-level
EuroQol (EQ-5D-5L). The five EuroQol domains of health are:
mobility, self-care, usual activities, pain/discomfort, and anx-
iety/depression. The higher the score on these domains, the
higher the level of complaints. To estimate the utility of health
states described by patients, we used the Dutch tariff22.
Quality-adjusted life years (QALYs) were calculated by means
of the Area Under the Curve (AUC) method. Higher QALYs
indicate more improvement in quality-of-life. The Dutch
guidelines for economic evaluations recommend the use of
this instrument for the measurement of utilities23,24.
Costs
To calculate the total societal costs, data were collected
within the above-mentioned time frame. For this, at first all
volumes of resource use were measured by means of online
questionnaires. Medication costs are calculated using the
Dutch Pharmaceutical Therapeutic compass (https://www.
farmacotherapeutischkompas.nl/). The costs of tools are val-
ued on the basis of actual purchase prices. The costs of the
CDT intervention are based on costs calculations of the
National Multiple Sclerosis Foundation. The Dutch Manual for
costing25 was used to calculate costs for all other categories
of costs. Besides healthcare costs, patient and family costs
were included. The cost of informal care was valued as a
“shadow price”, meaning the hourly wage rate of a profes-
sional caregiver (e.g. housekeeper). Travel costs were calcu-
lated by multiplying the average distance, with standard
price weights corrected for public transport costs and park-
ing costs25.
All costs reported in this study are expressed in Euros (e);
the year 2014 is used as a reference year. Discounting was
not necessary, since the follow-up period of the study did
not exceed 1 year. Table 1 provides an overview of all cost
categories, noting the unit of measurement used to measure
the different costs and the unit prices.
Table 1. Unit prices for healthcare and non-healthcare costs.
Cost category Unit Cost per unit
(Euros)
Healthcare (inpatient)a
Rehabilitation centre Night 460
Hospital Night 476
Nursing home Night 168
Healthcare (outpatient)a
Hospital day treatment Day 276
Specialists Contact 91
Activity therapy Contact 34
Occupational therapy Contact 33
Exercise therapy Contact 34
Physiotherapy Contact 33
Social work Contact 65
Speech therapist Contact 30
Psychologist/psychotherapist Contact 94
Psychiatrist Contact 94
Psychiatric nurse Contact 73
Other healthcare professionals Contact 62
General practitioner Contact 66
Family care at home Hours 58
Personal care at home Hours 73
Paid help Hours 23
Medicationb – –
Intervention costc – 2,527




Patient and family costsa
Travel costs Other various
Informal care Hours 14
Other sectorsa
Productivity losses Hours 34.75
aDutch Manual for costing.
bDutch Pharmaco Therapeutic compass.
cCalculated only for CDT group, based on costs calculations the National
MS Foundation.
dActual purchase prices.
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Analytical methods
All statistical analyses were performed using the Statistical
Package for the Social Sciences version 21 and Microsoft
Excel (Office 2010). Missing values were imputed using mul-
tiple imputation methods. As predictors for matching in the
various regression models, the following baseline parameters
were used: age, gender, disease duration, living situation,
marital status, education, work status, EDSS score, and num-
ber of co-morbidities. The clinically meaningful difference of
outcomes was defined as a half of the standard deviation
(SD) of that specific score at baseline26.
The incremental cost-effectiveness ratios (ICERs) were cal-
culated by dividing the incremental costs by the incremental
effects; we calculated the ICER by dividing the incremental
costs by the differences in MSSES Control. In the base case
analyses, the costs from a societal perspective were taken
into account, as well as the MSSES Control score at 6
months. For the CUA, the QALYs of every individual patient
and the societal costs were used to calculate the incremental
cost utility ratio’s (ICURs). Because cost data are generally
known to be skewed, we used non-parametric bootstrap-
ping, using 5,000 replications, to estimate the uncertainty
surrounding the cost-effectiveness ratio. A cost-effectiveness
plane (CE-plane) was drawn by presenting the bootstrapped
cost-effectiveness pairs. CE-planes show differences in effect
on the horizontal axis and in costs on the vertical axis.
Bootstrapped cost-effectiveness pairs located in the north-
west quadrant indicate the CDT to be inferior to conven-
tional care (more costly and less effective); in the southeast
quadrant to be superior (more effective and less costly), and
with respect to the northeast and southwest quadrants, the
preference for an intervention depends on the threshold
value, i.e. what society is prepared to pay for a gain in effect-
iveness, or is willing to accept as savings for a loss in
effectiveness.
Statistically significant differences in costs were deter-
mined by means of a 95% confidence interval (95% CI). The
uncertainty interval is represented by the 2.5th and 97.5th
percentiles; when the interval does not include zero, the dif-
ference is statistically significant. The probability of CDT
being a cost-effective alternative in comparison with usual
care is also demonstrated by a cost-effectiveness acceptabil-
ity curve (CEAC). A CEAC shows the probability of an inter-
vention being a cost-effective alternative for a certain
threshold value, viz. the amount of money a society is willing
to pay (WTP) for an improvement in QALY. The WTP thresh-
old for a QALY differs per country or even within countries.
In the Netherlands, the Dutch Council of Public Health and
Care published a report in 2006 regarding the burden of dis-
ease in the Netherlands, estimating a QALY threshold for MS
at e40,000 Euros27. No WTP has been established for the
MSSES Control.
Sensitivity analyses
We performed nine one-way sensitivity analyses (SEAs) to
test the robustness of the findings. In two analyses, the
perspective of the analyses was changed, from a societal to
a healthcare perspective for both outcomes (MSSES Control
(SEA1) and QALY (SEA2), meaning that all non-healthcare
costs (tools, travel, informal care, over the counter medica-
tion, and productivity losses) were not taken into account.
In one SEA (SEA3) the baseline MSSES Control of the control
group and the 6 months MSSES Control of the intervention
group were used to investigate the impact of a “waiting list
effect”. In four other SEA (SEA4–SEA7) the costs of the inter-
vention were decreased by, respectively, 500 or 1,000 Euros
for both endpoints. One other SEA (SEA8) was performed to
investigate the impact of the UK Tariffs for EQ-5D utilities on
the study results28. In a final SEA (SEA9), the results of the
scores on the SF-26 (version 1) of the MSQol-54 were used
to calculate the SF-6D utilities29. This was done in order to
investigate the possible discrepancies between EQ-5D and
SF-6D30. As there are no Dutch tariffs available, the UK tariffs
were used31.
Sub-group analyses
In total, 12 sub-group analyses (SUAs) were performed to
identify potential sub-groups of patients. For the first eight
SUAs, the same sub-groups were used for both study out-
comes (MSSES Control [SUA1-SUA3-SUA5-SUA7] and Dutch
QALY EQ-5D [SUA2-SUA4-SUA6-SUA8]). In the first two SUAs
[SUA1 and SUA2] only patients showing a clinically meaning-
ful increase in MSSES Control at 6 months were selected
(75 or more points); in two other SUAs [SUA3 and SUA4], the
50% of the patients with the lowest MSSES Control scores at
baseline were selected. The selection of the other four SUAs
was based on a recent report of an intense social cognitive
intervention in patients with treatment-resistant chronic
pain32; patients were included in this study if they reported
(1) relational problems with their support partner, (2) stres-
sors, and (3) distress, depression, or anxiety. Sub-groups of
patients were obtained by selecting those who experienced
all three factors [SUA6 and SUA8], and those having depres-
sive or anxious symptoms [SUA5 and SUA7]. In the next
SUAs [SUA9 and SUA10] the same two sub-groups were
used, but now the SF-6D (UK tariff) was used as a study
outcome. Protocol deviations were identified by screening all
study and medical data. In the two final SUAs [SUA11 and




Patients with MS were recruited from January 1, 2013 to
April 1, 2016, by the National Multiple Sclerosis Foundation
in the Netherlands. Two hundred and seventy-two patients
were assessed regarding their eligibility for participation in
this study (Figure 1). Seventy-eight patients (28.7%) did not
meet the inclusion criteria, and 36 patients (13.2%) did
not want to participate in the study. A total of 158 patients
(58.1%) were included in this study. Seventy-nine
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patients (50%) were allocated to the CDT group, and 79
patients (50%) to the control group. Protocol violations were
observed in five (6.3%) CDT patients and seven (8.9%) con-
trol patients. Two patients in the CDT group left the week-
end before it ended; the other patients had psychiatric
outpatient consultations before inclusion.
The mean age of the participants was 40 years, and 80%
of them were females. At the start of study participation
50% of the patients had a partner, 47% had higher educa-
tion, and 37% were employed. Overall, the baseline charac-
teristics showed no differences between the two groups
(Table 2).
The MSSES Control scores, Dutch EQ-5D-5L utilities, Dutch
QALYs, UK SF-6D utilities, and UK QALYs are reported in
Table 3. At 6 months, none of these outcomes were signifi-
cantly different between the two groups. At 1 month and 3
months, the MSSES Control was significantly higher in the
CDT group in comparison with controls. At the follow-up
period of 6 months for the CDT group, a clinically meaning-
ful increase was reported for MSSES Control in comparison
with baseline.
At 6months the total societal costs were significantly
higher for the CDT group (e13,439) in comparison with the
control group (e10,490), with a mean difference (95% CI) of
e2,913 (e140; e5,371). The healthcare costs were also signifi-
cantly higher in the CDT group in comparison with the
control group, which had a mean (95% CI) of e3,116 (e1,353;
e4,929) at 6months. Overall, the consumption of care did
not differ significantly between the two groups. However,
due to the higher (although not significantly so) costs of
prescribed medication and intervention costs, the total costs
for the CDT group were higher. On the other hand, the costs
of day treatment were lower, but not significantly different,
for the CDT group in comparison with care as usual. The
total non-healthcare costs were similar for both groups
(control e3,187; CDT e2,998), although the costs of tools,
informal care, and productivity losses were different (but not
significantly so) between both groups. Further details are
presented in Table 4.
Table 2. Baseline characteristics of patients in the CDT and control groups.
Characteristic Sample size (CDT/control) CDT (n¼ 79) Control (n¼ 79)
Gender, n (%) 79/79
Male 9 (11.4) 10 (12.7)
Female 70 (88.6) 69 (87.3)
Age, mean ± SD 79/77 41 (8.7) 40 (9.4)
Living situation, n (%) 75/73
Alone 16 (20.3) 15 (19.0)
Two or more people 59 (74.6) 58 (73.3)
Marital status, n (%) 75/73
Living together/married 50 (63.3) 44 (55.7)
Single 19 (24.1) 18 (22.8)
Divorced 5 (6.3) 7 (8.9)
Other 1 (1.3) 4 (5.1)
Education, n (%) 75/73
Primary school or lower (professional) education 2 (2.5) 3 (3.8)
Middle (professional) education 26 (33.0) 31 (39.3)
Higher (professional) education 47 (59.5) 39 (49.4)
Work status, n (%) 79/79
(Self) employed 26 (32.9) 37 (46.9)
Disabled 35 (44.3) 34 (43.0)
Sick leave 19 (24.1) 18 (22.8)
Voluntary work 21 (26.6) 16 (20.3)
Applicant for job 17 (21.5) 5 (6.3)
Other (student, retired) 11 (14.0) 4 (5.1)
Self-reported health disorders, n (%) 75/73
No 69 (87.3) 64 (81.0)
Yes 6 (7.6) 9 (11.4)
EDSS score, mean ± SD 78/52 2.3 ± 1.03 2.3 ± 1.13
Abbreviations. SD, standard deviation; EDSS, Expanded Disability Status Scale; CDT, Can Do treatment.
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Figure 1. Patient profile.
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Base case analysis
The base case CEA, from a societal perspective with MSSES
Control as outcome, showed that the CDT group induced
more costs (e2,948) but also more effects (40.74), resulting in
a small ICER (e72) (Table 5). Almost all bootstrapped ICERs
(95%) were located in the northwest quadrant of the CE-
plane (Figure 2) indicating both higher costs and higher
effects for the CDT intervention.
The base case CUA, from a societal perspective with
Dutch QALYs (EQ-5D-5L)22 as outcome, showed that CDT
patients gained less QALYs in comparison with control
patients (mean ¼ 0.02). Less QALYs gained, combined with
higher societal costs (e2,948) induced by CDT, resulted in an
inferior ICUR. As presented in Figure 3, 87% of the boot-
strapped ICURs were located in the northwest quadrant
(lower effects and higher costs) of the CE-plane, whereas
only 10% of the bootstrapped ICURs were located in the
northeast quadrant (higher effects and higher costs). An
important additional observation is that the QALY difference
between the two groups is very small and, as already men-
tioned in the ANCOVA analyses, not significantly different
between the two groups.
The CEACs of MSSES Control and QALY are presented in
Figures 4 and 5. The slope of the MSSES Control CEAC indi-
cates that, with a WTP threshold of e5,000, there is a high
probability that the CDT intervention is worth investing in.
For the CEACs with the QALY as an outcome, there is a small
chance of the CDT treatment being cost-effective. Using a
WTP threshold of e40,000, the QALY CEAC indicates that the
chance that the CDT intervention will be cost-effective
is zero.
Sensitivity analyses
In the first two SEAs, estimating total costs from a healthcare
perspective resulted in rather similar ICER and ICUR distribu-
tions among the various quadrants of the CE-plane for both
outcome measures [SEA1–2]. There was also little difference
in the outcome measures for the two groups for SEA3, where
the impact of having the opportunity to receive CDT after
the controlled study phase was investigated. Four sensitivity
analyses were performed to estimate the impact of lowering
the price of the intervention on the cost-effectiveness results
[SEA4–7]. The analyses proved the robustness of the base
case assumption for this parameter for both the MSSES
Control and QALYs; no major changes were found in distri-
butions on the CE plane (Tables 5 and 6). A remarkable dif-
ference was observed in the final SEA [SEA9], in which the
SF-6D with the UK tariff was used to calculate the QALYs.
Eighty-five per cent of the ICURs are situated in the north-
east quadrant, indicating a high chance of the CDT being
cost-effective.
Sub-group analyses
Overall, the sub-group analyses of the ICERs and ICURs show
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there is a high chance that ICERs with MSSES Control as
outcome are situated in the northwest quadrant (higher
costs and higher effects) and ICURs with EQ-5D-5L QALY as
outcome lie in the northeast quadrant (higher costs and
lower effects). When the QALYs were calculated using SF-6D
[SUA4-9-10], the distribution of the ICURs among the differ-
ent quadrants shows the same relevant changes as we found
in the sensitivity analyses. In other words, the probability
that CDT is cost-effective increases when using SF-6D as
an outcome.
Discussion
This trial-based evaluation is the first economic evaluation of
the intense cognitive therapy-based intervention (CDT) in
patients with RRMS. The results with a 6months follow-up
are not conclusive: cost-effectiveness analyses show a high
chance of CDT being the preferred treatment—although it is
somewhat more expensive, it also induces more effects on
the self-efficacy control scale. However, the cost-utility ana-
lysis using QALYs based on the EQ-5D-5L questionnaire indi-
cates the opposite—a very small chance of CDT being cost-
effective. Even so, when using QALYs based on SF-6D for the
CUA, there is a higher probability that CDT is preferred over
care as usual. All other sensitivity analyses confirm these
analyses. The results of the sub-group analyses show that
no relevant sub-groups of patients with RRMS could
be identified.
In our opinion, there are two main reasons, which explain
these study findings. First, the societal costs were signifi-
cantly higher for the CDT group, in comparison with the care
as usual group. Although lower costs for productivity losses
(absence from work) and for day treatment were observed
Table 4. Average imputed resource use and costs (Euros) at 6-month follow-up for CDT and control group patients.
Cost category Unit Control group (n¼ 79) CDT group (n¼ 79) Bootstrap analyses
Average use (SD) Average costs
Euro’s (SD)








Night 0.86 (5.71) 396 (2,626) 0.87 (2.63) 399 (1,209)
Hospital
admission
Night 0.25 (0.74) 115 (347) 0.48 (0.93) 223 (434)




Day 3.7 (12.94) 1,016 (3,571) 2.3 (4.24) 624 (1,169) e 394 (e430) (e1,323, e 269)
Specialists Contact 4.2 (6.10) 384 (555) 4.5 (4.77) 406 (434)
Activity therapy Contact 0.60 (1.61) 20 (55) 0.69 (2.39) 23 (81)
Occupational
therapy
Contact 1.7 (3.99) 54 (132) 2.1 (4.09) 70 (132)
Exercise therapy Contact 1.7 (6.22) 59 (212) 2.4 (5.18) 81 (176)
Physiotherapy Contact 13.5 (16.70) 446 (551) 13.3 (15.29) 437 (504)
Social work Contact 0.97 (2.45) 63 (159) 0.99 (1.78) 65 (116)
Speech therapist Contact 0.21 (1.10) 6 (33) 0.15 (0.33) 4 (10)
Psychologist/
psychotherapist
Contact 3.4 (5.28) 317 (496) 3.4 (4.48) 318 (421)
Psychiatrist Contact 0.59 (1.61) 55 (152) 0.71 (1.19) 66 (112)
Psychiatric nurse Contact 0.25 (0.98) 18 (72) 0.25 (0.66) 18 (48)
Other healthcare
professionals
Contact 3.28 (6.73) 203 (417) 1.7 (2.50) 105 (155)
General
practitioner
Contact 2.4 (1.98) 159 (131) 2.9 (2.76) 193 (182)
Family care
at home
Hours 0.04 (0.16) 2 (9) 0.45 (1.59) 26 (92)
Personal care
at home
Hours 0.25 (1.22) 18 (89) 0.20 (0.55) 15 (40)
Paid help Hours 0.45 (2.53) 10 (58) 4.2 (14.58) 96 (335)




Sub-total 7,303 (6,644) 10,440 (4,756) (e3,116, e931) (e1,353 , e4,929)
Non-healthcare
Tools Various 110 (305) 243 (459)
Travel costs Various 160 (164) 154 (128)
Informal care Hours 55.3 (74.58) 732 (1,044) 66.5 (102.53) 931 (1,435)
Over the coun-
ter medication
Various 43 (124) 42 (70)
Productivity
losses
Hours 61.6 (131.7) 2,141 (4,577) 46.8 (103.1) 1,627 (3,584)
Sub-total 3,187 (4,880) 2,998 (3,943) e215 (e698) (e1,590, e1,164)
Total societal costs 10,490 (9,740) 13,439 (6,707) e 2,913 (e1,341) (e140, e5,371)
Not statistical significant difference (p<0.05), **Statistical significant difference (p<0.05).
AIS, Athens Insomnia Scale; MHR-QOL, Menopausal Health-Related Quality of Life; HADS, Hospital Anxiety and Depression Scale; POMS, Profile of Mood States;
ZC, zero-crossing; METs, metabolic equivalents
Abbreviations. CDT, Can Do Treatment; SD, standard deviation; NA, not applicable; 95% CI, 95% confidence interval.
JOURNAL OF MEDICAL ECONOMICS 7
for the CDT group, total costs were higher for this group.
The costs of the intervention and the prescribed medication
costs were the main drivers for the higher costs in the
CDT group. Second, the MSSES Control or the self-efficacy
outcome is more sensitive than the EQ-5D-5L for detecting
clinically relevant changes in patients with RRMS in the
current study. This is also expected, as MSSES control is a
disease-specific measure and EQ-5D is a generic measure.
The use of the EQ-5D in patients with MS has some import-
ant drawbacks, which will be discussed later in this discus-
sion section.
The potential value in MS of treatments comparable to
CDT—cognitive behavioural therapy and educational
interventions—has been acknowledged by others33,34. Based
on a systematic review, 15 randomized controlled trials were
identified evaluating non-pharmacological interventions in
patients with MS using self-efficacy as an outcome6–14,35–40.
These studies were performed in the US (n¼ 5), UK (n¼ 5),
Italy (n¼ 1), and Australia (n¼ 1). The interventions were
very heterogeneous (e.g. content, intensity, duration, length
of each session), but could be categorized as follows; self-
management (n¼ 5), cognitive behavioural therapy (CBT)
and education (n¼ 2), exercise based CBT (n¼ 3), and other
types of interventions (n¼ 5). Four6,7,12,35 out of five studies
evaluating self-management interventions show a significant
treatment effect on self-efficacy in patients with MS. For the
Table 5. Incremental cost-effectiveness ratios and cost-effectiveness plane distributions between CDT and control groups of 6-month follow-up for MSSES con-
trol as outcome.






Societal perspective & MSSES Control 79/79 e72 40.74/e2,948 4 0 95 2
Sensitivity analyses (SE)
SEA1 Healthcare perspective 79/79 e77 40.74/e3,137 4 0 96 0
SEA3 Societal perspective Baseline MSSES
control as outcome for control group
79/79 e38 78.51/e2,948 0 0 98 2
SEA4 Societal perspective minus 500 inter-
vention costs
79/79 e60 40.74/e2,448 4 0 93 4
SEA5 Societal perspective minus 1,000 inter-
vention costs
79/79 e48 40.74/e1,948 4 0 89 7
Subgroup analyses (SU)
SUA1 Societal perspective of responders
(increase of > 75 points
MSSES control)
17/40 e149 19.83/e2,963 26 2 67 6
SUA3 Societal perspective & MSSES control
(50% with lowest score on
MSSES control)
39/37 e61 44.44/e2,689 4 0 84 11
SUA5 Societal perspective & MSSES control
(all factors)
61/68 e101 32.73/e3,292 10 0 88 2
SUA7 Societal perspective & MSSES control
(anxiety or depression)
36/43 e33 51.95/e1,693 5 1 74 20
SUA11 Per protocol analyses 72/74 e75 36.33/e2,724 6 0 91 3
Abbreviations. ICER, Incremental Cost-Effectiveness Ratio; SEA, Sensitivity analysis; SUA, Subgroup analysis; All factors, anxiety, depression, health distress, stres-
sors, or relation problems; CDT, Can Do treatment; northwest quadrant: CDT less effective and more costly compared to control; southwest quadrant: CDT less
effective and less costly compared to control; northeast quadrant: CDT more effective and more costly compared to control; southeast quadrant: CDT more


















Figure 2. Cost-effectiveness plane with bootstrapped ICERS; societal costs and MSSES Control at 6months. Abbreviation. ICERs, Incremental Cost
Effectiveness Ratios.
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exercise-based CBT interventions, no between-group effects
were identified14,37,38. For CBT and education and other
interventions, mixed results were reported. Our RCT showed
that self-efficacy improved in patients with MS after an inten-
sive 3-day social cognitive treatment; however, as this inter-
vention was not comparable to the 15 other studies, no
conclusions could be drawn in relation to the findings of
these studies.
The need for economic evidence on this topic is very evi-
dent as, by means of a rapid systematic review, only two
trial-based (full) economic evaluations of non-pharmaco-
logical interventions in patients with MS were identified. The
first study was a trial-based economic evaluation of a prag-
matic exercise intervention (EXIMS) for people with MS41,
and used EQ-5D, SF-6D, and QALYs as outcomes. The cost-
effectiveness analyses were performed from the National
Health Services and personal social service provider (Third
Party Payer) perspectives, in other words only taking into
account the medical costs. The results of this study were the
opposite of our findings. They concluded that the EXIMS
intervention was cost-effective, although the costs were
somewhat higher, but the QALYs were also higher (for EQ-
5D and SF-6D) for EXIMS group. The second study was also a
trial-based economic evaluation of a group-based fatigue
management programme (FACETS) for people with MS39.
They included the fatigue self-efficacy scale, EQ-5D, SF-6D,
and QALYs as outcomes. Cost-effectiveness analyses were
performed from the same perspectives as used in the EXIMS
study. The FACETS study is in line with our findings; it stays
unclear whether the intervention is cost-effective, as the
QALY differences are very small and costs were higher for
the treatment arm39.
The challenges for outcome measurement in this study
were considered substantial. The EQ-5D and SF-6D are rec-
ommended utility measures23 and are widely used across dis-

















Figure 3. Cost-effectiveness plane with bootstrapped ICURS: societal costs and Dutch (EQ-5D-5L) QALY at 6months. Abbreviations. QALY, Quality-Adjusted Life
Years; ICURS, Incremental Cost-Utility Ratios.

























Figure 4. Cost-effectiveness acceptability curve for the social costs and MSSES Control at 6months. Abbreviation. ICER, Incremental Cost Effectiveness Ratio.
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drawbacks44. These two questionnaires show similarities and
dissimilarities in items, domains, scoring, and valuation meth-
ods, they generate different utility scores45. In a recent sys-
tematic review, the psychometric properties of utility
measures in patients with MS were summarized44. Based on
the study of Fogarty et al.46, the content validity of EQ-5D
and SF-6D for MS was questioned. These questionnaires miss
relevant domains, like “cognition”, “disability” (both question-
naires), and “fatigue” (EQ-5D). In addition, they also show
problems of differentiating between the different levels of
disability44. This lack of discriminative ability could be caused
by the fact that there is not enough improvement possible

























Figure 5. Cost-effectiveness acceptability curve for societal costs and Dutch (EQ-5D-5L) QALY at 6months. Abbreviation. ICER, Incremental Cost Effectiveness Ratio.
Table 6. Incremental cost-utility ratios and cost-effectiveness plane distributions between CDT and control groups of follow up 6 months for QALY as outcome.
Number QALY Patients
(control/ CDT)





Societal perspective and Dutch QALY EQ-5D 79/79 Inferior 0.02/€2.948 87 10 1 1
Sensitivity analyses
SEA2 Healthcare perspective and Dutch QALY EQ-5D 79/79 Inferior 0.02/€3.317 89 11 0 0
SEA6 Societal perspective minus 500 intervention
costs and Dutch QALY EQ-5D
79/79 Inferior 0.02/€2.448 86 10 2 1
SEA7 Societal perspective minus 1000 intervention
costs and Dutch QALY EQ-5D
79/79 Inferior 0.02/€1.948 83 9 5 3
SEA8 Societal perspective and UK QALY EQ-5D 79/79 Inferior 0.02/€2.948 89 9 1 1
SEA9 Societal perspective and UK QALY SF-6D 79/79 €862.667 .00/€2.948 17 81 0 2
Subgroup analyses
SUA2 Societal perspective and Dutch QALY EQ-5D
(50% lowest score on MSSES Control)
40/39 Inferior 0.05/€2.407 86 1 13 0
SUA4 Societal perspective and UK QALY SF-6D (50%
lowest score on MSSES Control)
39/37 €733.280 .00/€2.407 24 63 4 9
SUA6 Societal perspective and Dutch QALY EQ-5D
(all factors)
61/68 Inferior 0.02/€3.292 83 15 1 1
SUA8 Societal perspective and Dutch QALY EQ-5D
(anxiety or depression)
36/43 Inferior 0.02/€1.693 73 7 14 6
SUA9 Societal perspective and UK QALY SF-6D
(all factors)
61/68 €831.113 .00/€3.292 16 82 0 2
SUA10 Societal perspective and UK QALY SF-6D (anx-
iety or depression)
36/43 €222.479 .01/€1.693 5 73 0 20
SUA12 Per protocol analyses 72/74 Inferior 0.02/€2.724 86 10 2 1
All factors, anxiety, depression, health distress, stressors or relation problem.
Abbreviations. ICUR, Incremental Cost-Utility Ratio; SEA, Sensitivity analysis; SUA, Subgroup analysis; QALY, Quality-Adjusted Life Year; CDT, Can Do treatment;
ICER, Incremental Cost- Effectiveness Ratio; northwest quadrant, CDT less effective and more costly compared to control; southwest quadrant, CDT less effective
and less costly compared to control; northeast quadrant, CDT more effective and more costly compared to control; southeast quadrant, CDT more effective and
less costly compared to control.
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in the utility scores for mildly impaired patients with MS.
This is confirmed in our study by a high proportion of ceiling
effects in all EQ-5D domains, ranging from 19.6% in the
domains “pain” and “discomfort” to 87.3% in the domain
“self-care” (data not shown). In the SF-6D domains “vitality”
and “role limitations”, ceiling effects were also observed,
respectively, 36.7% and 22.2%. Others also reported ceiling
effects in SF-6D and EQ-5D in patients with MS46–48.
In our study the patients with MS were mildly impaired,
with a mean EDSS score of 2.3, indicating that they have on
average a mild disability in only one functional system or
minimal disability in two functional systems49. Based on our
data, it seems that the EQ-5D-5L was better able to detect
differences in HRQoL in comparison with the SF-6D, although
the observed differences were neither significantly different
nor clinically relevant. In summary, it is clear that both EQ-
5D and SF-6D show shortcomings for the measurement of
HrQoL in patients with MS. In addition, it is also evident that
they cannot generally be used interchangeably for measure-
ment of preference utilities30,50. However, it was not possible
to explain the discrepancy between EQ-5D-5L and SF-6D
findings based on the results of our study.
For economic evaluations, although differences in utilities
or QALYs between groups are small, they can influence the
distribution of the ICURs over the CE-plane quadrants and,
hence, the study conclusions51,52. In our study, the impact of
using EQ-5D vs SF-6D was essential for the distributions of
the ICURs among the different quadrants. All analyses with
the EQ-5D show inferior results for the CDT group, and when
using the SF-6D there is a high probability of ICURs being
cost-effective. Of five trials investigated52, in one study—
evaluating a nurse-led telemedicine intervention for asthma
patients—the use of the utility measures was critical for the
probability of the experimental treatment being cost-effect-
ive53. In our opinion, we are not able to judge which of the
two ICUR analyses we should follow for drawing conclusions
for decision-making and the implementation of CDT. This is
also based on the fact (as discussed before) that the content
validity and the discriminative ability of both questionnaires
(EQ-5D-5L and SF-6D) are limited in patients with MS47.
Strengths of the current study include the large sample
size, and the recruitment of patients from all over the
Netherlands, increasing the generalizability of study findings.
In addition, the number of patients who were not treated
according to the protocol was low (<10%), and the data ana-
lysis was performed by an independent researcher not
involved in the study design or treatment. Furthermore, the
current study provides new evidence, as there have been no
previous economic evaluations of an intense cognitive the-
ory-based intervention for MS performed in a randomized
controlled trial setting. Finally, the cost-effectiveness analyses
were conducted from a societal perspective with a bottom-
up detailed method of costing, and reported according to
the CHEERS guidelines54. In addition, the Dutch guidelines
for performing economic evaluations were followed as much
as possible23,25, which we also consider to be a strength.
The study has several drawbacks. First, a 6-month follow-
up may be too short to adequately evaluate the cost-
effectiveness of an intervention with a potentially longer last-
ing effect, especially in patients with a chronic disease.
Second, the increase in control self-efficacy at 6 months in
care-as-usual patients, which was unexpected. In principle,
the comparator should be the most cost-effective alternative
intervention currently available, and in practice the compara-
tor is usually the most widely used alternative treatment55.
However, as there is no effective alternative treatment for
improving control self-efficacy in patients with MS, we chose
care as usual. The fact that control patients were given the
opportunity to receive CDT after the controlled study phase
may have induced an effect comparable to that of being on
a waiting list. Actually, 77% of the control patients chose to
receive CDT. It is well known that the choice of comparator
is a critical design parameter in economic evaluation
research, and that the comparator may influence
study results56.
Practical implications of the study findings and
current knowledge base
The following findings are useful for decision-makers:
1. Based on the cost-effectiveness analysis, CDT improves
the self-efficacy in patients with RRMS and low disability
and generates higher costs compared to the care as
usual patients.
2. The total cost of CDT was estimated to be 2.500 Euros,
taking into account all healthcare provider costs and the
weekend stay in a hotel. However, a substantial amount
of these costs can be reduced by choosing a cheaper
treatment location. For instance, instead of using a
hotel, an outpatient rehabilitation clinic.
3. The findings related to cost-utility analyses of the CDT
need to be interpreted with caution. There is a growing
evidence base to suggest that the EQ-5D and SF-6D
may lack both relevance and sensitivity to changes47.
For research this poses a question to investigate: which
preference based utility instrument is the most reliable
one in patients with MS and also in other disease
populations?
4. CDT is a standardized intervention, which has been
described in detail in order to make replication of the
treatment and further research possible15,16,19.
5. The study population of the current study was recruited
on a national level, indicating that study findings are
generalizable to patients with RRMS with low disability
in other western countries.
6. This CDT could also be applicable to other populations:
in one observational study, a similar intervention was
successful in patients with intractable chronic pain32. In
addition, the effects of CDT may be expected to be gen-
eralizable to other (western) societies, as is suggested in
the study by Ng et al.57 on a similar intervention in
American patients with MS.
7. No relevant sub-groups could be identified in our study.
In other words, there is no reason to exclude patients
for the CDT who are not anxious, have no depressive
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feelings, experience more health distress or stressors,
and those who report relational problems. This also
holds for selection of patients of MSSES control
at baseline.
Conclusions
Results of this trial-based economic evaluation are not con-
clusive on the implementation of CDT for patients with
RRMS and low disability. When using the EQ-5D-5L tariffs to
calculate a QALY, CDT is not a cost-effective alternative in
comparison to care as usual. However, when using self-effi-
cacy or SF-6D as outcomes, there is a probability that CDT is
cost-effective. Future research is needed to investigate
whether CDT is cost-effective in comparison with care as
usual. In these future studies, the follow-up time should be
extended. In addition, SF-6D should be used in sensitivity
analyses of economic evaluations of MS treatments, as it
shows opposite effects in comparison with the EQ-5D.
Another option for measurement of utilities could be the
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